Bioventus Inc.
BVS
Positions held
Your positionsBVS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Bioventus Inc. operates in the growing medical devices sector, focusing on innovative solutions for musculoskeletal health, which positions it well against competitors in a high-demand market.
- In Q2 2026, Bioventus reported a revenue increase of 16% compared to the previous quarter, reaching $153 million.
- The company's gross margin improved to 69% in Q2 2026, up from 68.7% in the prior quarter.
- Despite its growth potential, Bioventus has a high debt-to-equity ratio of 95.075, which raises concerns about financial stability and risk management.
- In 2023, Bioventus experienced a significant net income loss of $156.23 million, indicating ongoing profitability challenges.
- The company's operating margin was only 0.4% in 2023, reflecting difficulties in managing operational costs effectively.
Fundamentals
| Market cap | $866.79M | Enterprise value | $1.15B | Trailing P/E | 16.27 | Forward P/E | 13.79 |
| PEG | 1.53 | Price / book | 3.79 | Beta | 0.64 | Dividend yield | 0.00% |
| Revenue growth | 3.8% | Earnings growth | 327.3% | Gross margin | 68.7% | Operating margin | 12.2% |
| Profit margin | 9.4% | ROE | 25.7% | ROA | 5.5% | Debt / equity | 0.95 |
| Current ratio | 1.69 | Free cash flow | $67.76M | Analyst recommendation | none | Mean target | $17.60 |
| 52w high | $15.89 | 52w low | $6.37 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $153M | $132M | $158M | $139M | $148M |
| Op margin | 12.2% | 6.7% | 13.8% | 8.1% | 12.4% |
| Net income | $33.4M | $3.1M | $14.8M | $3.2M | $7.5M |
| Gross margin | 69.0% | 68.7% | 68.9% | 68.0% | 69.1% |
| Gross profit | $106M | $90.8M | $109M | $94.2M | $102M |
| Operating income | $18.7M | $8.9M | $21.7M | $11.3M | $18.4M |
- Revenue +16% vs prior quarter ($153M vs $132M).
- Gross margin 69% (was 68.7% prior quarter).
- Operating margin expanded to 12.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $568M | $573M | $512M | $512M | — |
| Op margin | 9.9% | 4.0% | 0.4% | -6.8% | — |
| Net income | $22.7M | -$36.1M | -$156M | -$159M | — |
| Gross margin | 68.3% | 67.7% | 64.1% | 64.6% | — |
| Gross profit | $388M | $388M | $328M | $331M | — |
| Operating income | $56.3M | $22.8M | $2.0M | -$34.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-24 · Are Medical Stocks Lagging Bioventus (BVS) This Year?
2026-08-20 · 4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
2026-08-13 · Bioventus (BVS) Q2 2026 Earnings Call Transcript
2026-08-10 · Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
2026-08-10 · The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance
2026-08-07 · Is Bioventus (BVS) Stock Undervalued Right Now?
2026-08-06 · Barrington Adjusts Price Target on Bioventus to $18 From $14, Maintains Outperform Rating
2026-08-06 · Bioventus Inc. Q2 2026 Earnings Call Summary
2026-08-05 · Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ...
2026-08-05 · Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed
2026-08-05 · Bioventus Q2 Earnings Call Highlights
2026-08-05 · Bioventus (BVS) Q2 Earnings Meet Estimates
Price (daily)
Full chart · RSI · MACD · patterns